23 results on '"Guirado L"'
Search Results
2. [Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients.]
- Author
-
López V, Mazuecos A, Villanego F, López-Oliva M, Alonso A, Beneyto I, Crespo M, Díaz-Corte C, Franco A, González-Roncero F, Guirado L, Jiménez C, Juega J, Llorente S, Paul J, Rodríguez-Benot A, Ruiz JC, Sánchez-Fructuoso A, Torregrosa V, Zárraga S, Rodrigo E, and Hernández D
- Abstract
SARS-CoV-2 infection (COVID-19) has had a significant impact on transplant activity in our country. Mortality and the risk of complications associated with COVID-19 in kidney transplant recipients (KT) were expected to be higher due to their immunosuppressed condition and the frequent associated comorbidities. Since the beginning of the pandemic in March 2020 we have rapidly improved our knowledge about the epidemiology, clinical features and management of COVID-19 post-transplant, resulting in a better prognosis for our patients. KT units have been able to adapt their programs to this new reality, normalizing both donation and transplantation activity in our country.This manuscript presents a proposal to update the general recommendations for the prevention and treatment of infection in this highly vulnerable population such as KT., (© 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.)
- Published
- 2022
- Full Text
- View/download PDF
3. History of urological malignancies before kidney transplantation, oncological outcome on the long term.
- Author
-
Boissier R, Hidalgo R, Rodríguez Faba O, Territo A, Subiela JD, Huguet J, Sánchez-Puy A, Gallioli A, Vanacore D, Mercade A, Martinez C, Palou J, Guirado L, and Breda A
- Subjects
- Humans, Male, Neoplasm Recurrence, Local, Retrospective Studies, Kidney Failure, Chronic, Kidney Transplantation, Urologic Neoplasms epidemiology, Urologic Neoplasms therapy
- Abstract
Introduction: We aimed to report the oncological outcomes of ESRD patients with histories of urological malignancies who were subsequently submitted to kidney transplantation (KT)., Material and Method: Retrospective study lead in the Puigvert Foundation (Barcelona) registry of 1,200 KT performed from 1988 to 2018. Eighty-five urological malignancies that were treated before KT in 81 patients were identified: 15 (18%) prostate cancers, 49 (58%) RCC, 19 (22%) urothelial carcinomas and 2 (2%) testicular cancers. Baseline characteristics, cancer staging, treatment and follow-up were registered as well as the chronology of the start of dialysis, inscription on the waiting list and kidney transplantation. Endpoints included were cancer recurrence, metastatic progression, cancer-specific death and overall survival., Results: In a median follow-up of 13.1 years (2.2-32), 16/85 (19%) cancer recurrences were reported, with 3 (4%) who progressed to metastasis and died of cancer. Median overall survival after cancer treatment was 25.3 years and cancer-specific survival was 95% at 25 years. Median time from cancer treatment to kidney transplantation was 4.8 years: 3.7 years in prostate cancer, 3.9 years in RCC and 8.8 years in bladder cancer. The median time from start of dialysis to kidney transplantation was 1.8 years in patients with histories of urological malignancy versus 0.5 year in the total cohort of 1,200 renal transplanted over the same period., Conclusions: Well-selected patients with histories of urological malignancies greatly benefit from kidney transplantation with infrequent and late cancer recurrence. Waiting time could be optimized in low-risk prostate cancer and RCC, but more robust data are needed., (Copyright © 2021 AEU. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
4. [Improved office blood pressure control by automatic delayed-reading oscillometric device].
- Author
-
Coll-Brito V, Calero F, Arias P, Ayasreh N, Ochoa J, Ramos A, Guirado L, and Fernández-Llama P
- Subjects
- Aged, Blood Pressure, Blood Pressure Determination, Blood Pressure Monitoring, Ambulatory, Humans, Male, Middle Aged, Hypertension diagnosis, Reading
- Abstract
Introduction: Office blood pressure (BP) measurement is a recommended procedure, although the out-of-office BP measurements are increasingly used., Objective: To know the degree of BP control by clinical measurement., Material and Methods: During November 2019 demographic and clinical data, office attended systolic BP (SBP) and diastolic BP (DBP) measured with an automatic device with delayed reading and, if performed, data from ambulatory BP monitoring (ABPM) were collected., Results: 102 patients (67 men) were included, with a mean age of 64.9 years, 30% diabetic and 34% with cardiovascular complications. 70% had a controlled hypertesion (<140/90 mmHg) by office BP, the mean SBP was 131 ± 16.5 mmHg and the DBP was 73 ± 9.5 mmHg. Old age and diabetes were associated with uncontrolled hypertension. Thirty three patients had ABPM data, which allowed them to be classified according to the 24-hour BP into: 30% true normotension, 9% white-coat hypertension, 15% sustained hypertension, and 45% masked hypertension., Conclusion: The use of automatic devices reduces the white-coat phenomenon, improving the % of patients with office BP controlled. However, this is not confirmed outside the clinic, showing the importance of ABPM in the evaluation of hypertension control. Office BP measurement is useful in patients initial assessment and also provides educational aspects, although the methodology must be optimized to define its clinical role., (Copyright © 2021 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
5. [A clinical management protocol for COVID-19 infection in pregnant women].
- Author
-
Valdés-Bango M, Meler E, Cobo T, Hernández S, Caballero A, García F, Ribera L, Guirado L, Ferrer P, Salvia D, Figueras F, Palacio M, Goncé A, and López M
- Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has caused a large global outbreak and has had a major impact on health systems and societies worldwide. The generation of knowledge about the disease has occurred almost as fast as its global expansion. Very few studies have reported on the effects of the infection on maternal health, since its onset. The mother and foetus do not seem to be at particularly high risk. Nevertheless, obstetrics and maternal-foetal medicine practice have made profound changes in order to adapt to the pandemic. In addition, there are aspects specific to COVID-19 and gestation that should be known by specialists. In this review an evidenced-based protocol is presented for the management of COVID-19 in pregnancy., (© 2020 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
6. [Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients].
- Author
-
López V, Vázquez T, Alonso-Titos J, Cabello M, Alonso A, Beneyto I, Crespo M, Díaz-Corte C, Franco A, González-Roncero F, Gutiérrez E, Guirado L, Jiménez C, Jironda C, Lauzurica R, Llorente S, Mazuecos A, Paul J, Rodríguez-Benot A, Ruiz JC, Sánchez-Fructuoso A, Sola E, Torregrosa V, Zárraga S, and Hernández D
- Subjects
- COVID-19, Comorbidity, Coronavirus Infections drug therapy, Coronavirus Infections epidemiology, Coronavirus Infections transmission, Humans, Immunosuppressive Agents therapeutic use, Pneumonia, Viral drug therapy, Pneumonia, Viral epidemiology, Pneumonia, Viral transmission, Risk Factors, SARS-CoV-2, Spain, Betacoronavirus, Coronavirus Infections prevention & control, Immunocompromised Host, Kidney, Pandemics prevention & control, Patient Education as Topic, Pneumonia, Viral prevention & control, Transplant Recipients
- Abstract
The SARS-CoV-2 (Covid-19) coronavirus pandemic is evolving very quickly and means a special risk for both immunosuppressed and comorbid patients. Knowledge about this growing infection is also increasing although many uncertainties remain, especially in the kidney transplant population. This manuscript presents a proposal for action with general and specific recommendations to protect and prevent infection in this vulnerable population such as kidney transplant recipients., (Copyright © 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications.
- Author
-
Bover J, Ureña-Torres P, Laiz Alonso AM, Torregrosa JV, Rodríguez-García M, Castro-Alonso C, Górriz JL, Benito S, López-Báez V, Lloret Cora MJ, Cigarrán S, DaSilva I, Sánchez-Bayá M, Mateu Escudero S, Guirado L, and Cannata-Andía J
- Subjects
- Chronic Kidney Disease-Mineral and Bone Disorder complications, Humans, Osteoporosis complications, Bone Density, Chronic Kidney Disease-Mineral and Bone Disorder therapy, Osteoporosis therapy
- Abstract
Osteoporosis (OP) and chronic kidney disease (CKD) both independently affect bone health. A significant number of patients with CKD have decreased bone mineral density (BMD), are at high risk of fragility fractures and have an increased morbidity and mortality risk. With an ageing population, these observations are not only dependent on "renal osteodystrophy" but also on the associated OP. As BMD predicts incident fractures in CKD patients (partI), we now aim to analyse the potential therapeutic consequences. Post-hoc analyses of randomised studies have shown that the efficacy of drugs such as alendronate, risedronate, raloxifene, teriparatide and denosumab is similar to that of the general population in patients with a mild/moderate decline in their glomerular filtration rate (especially CKD-3). These studies have some flaws however, as they included mostly "healthy" women with no known diagnosis of CKD and generally with normal lab test results. Nevertheless, there are also some positive preliminary data in more advanced stages (CKD-4), even though in CKD-5D they are more limited. Therefore, at least in the absence of significant mineral metabolism disorders (i.e. severe hyperparathyroidism), the potential benefit of these drugs should be considered in patients with a high or very high fracture risk. It is an important change that the new guidelines do not make it a requirement to first perform a bone biopsy and that the risk/benefit ratio of these drugs may be justified. However, we must also be aware that most studies are not consistent and the level of evidence is low. Consequently, any pharmacological intervention (risk/benefit) should be prudent and individualised., (Copyright © 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
8. Kidney transplant from controlled donors following circulatory death: Results from the GEODAS-3 multicentre study.
- Author
-
Portolés JM, Pérez-Sáez MJ, López-Sánchez P, Lafuente-Covarrubias O, Juega J, Hernández D, Espí J, Navarro MD, Mazuecos MA, Rodríguez-Ferrero ML, Maruri-Kareaga N, Moreso F, Melilli E, de Souza E, Ruiz JC, Llamas F, Gutiérrez-Dalmau A, Guirado L, Martín-Moreno P, Pérez Flores I, Fernández-García A, Jiménez C, Gavela E, Ramos A, and Pascual J
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Cause of Death, Child, Child, Preschool, Cold Ischemia adverse effects, Cold Ischemia statistics & numerical data, Delayed Graft Function epidemiology, Delayed Graft Function etiology, Female, Glomerular Filtration Rate, Graft Survival, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Organ Preservation methods, Retrospective Studies, Spain, Time Factors, Transplant Recipients statistics & numerical data, Treatment Outcome, Young Adult, Heart Arrest mortality, Kidney Transplantation mortality, Kidney Transplantation statistics & numerical data, Tissue Donors statistics & numerical data
- Abstract
Introduction: Many European countries have transplant programmes with controlled donors after cardiac death (cDCD). Twenty-two centres are part of GEODAS group. We analysed clinical results from a nephrological perspective., Methods: Observational, retrospective and multicentre study with systematic inclusion of all kidney transplant recipients from cDCD, following local protocols regarding extraction and immunosuppression., Results: A total of 335 cDCD donors (mean age 57.2 years) whose deaths were mainly due to cardiovascular events were included. Finally, 566 recipients (mean age 56.5 years; 91.9% first kidney transplant) were analysed with a median of follow-up of 1.9 years. Induction therapy was almost universal (thymoglobulin 67.4%; simulect 32.8%) with maintenance with prednisone-MMF-tacrolimus (91.3%) or combinations with mTOR (6.5%). Mean cold ischaemia time (CIT) was 12.3h. Approximately 3.4% (n=19) of recipients experienced primary non-function, essentially associated with CIT (only CIT ≥ 14 h was associated with primary non-function). Delayed graft function (DGF) was 48.8%. DGF risk factors were CIT ≥ 14 h OR 1.6, previous haemodialysis (vs. peritoneal dialysis) OR 2.1 and donor age OR 1.01 (per year). Twenty-one patients (3.7%) died with a functioning graft, with a recipient and death-censored graft survival at 2-years of 95% and 95.1%, respectively. The estimated glomerular filtration rate at one year of follow-up was 60.9 ml/min., Conclusions: CIT is a modifiable factor for improving the incidence of primary non-function in kidney transplant arising from cDCD. cDCD kidney transplant recipients have higher delayed graft function rate, but the same patient and graft survival compared to brain-dead donation in historical references. These results are convincing enough to continue fostering this type of donation., (Copyright © 2018 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
9. Three cases of monoclonal gammopathy of renal significance after kidney transplantation. De novo C3 glomerulopathy.
- Author
-
Serra N, Facundo C, Canal C, Arce Y, Ayasreh N, Vila A, Bardají B, Silva I, López V, Benito S, Ballarín J, and Guirado L
- Subjects
- Aged, Female, Glomerulonephritis diagnosis, Glomerulonephritis drug therapy, Glomerulonephritis etiology, Humans, Kidney Diseases immunology, Kidney Diseases surgery, Male, Middle Aged, Paraproteinemias immunology, Polycystic Kidney Diseases complications, Postoperative Complications drug therapy, Postoperative Complications immunology, TRPP Cation Channels genetics, Complement C3, Kidney Diseases etiology, Kidney Transplantation adverse effects, Paraproteinemias complications, Postoperative Complications etiology
- Abstract
Monoclonal gammopathy of renal significance includes all renal disorders caused by a monoclonal immunoglobulin secreted by a non-malignant B-cell clone. Patients with MGRS do not, by definition, meet criteria for multiple myeloma, with haematological disorders generally considered to be monoclonal gammopathy of undetermined significance. Nevertheless, the renal involvement can be serious and require specific treatment. Monoclonal gammopathy of renal significance is associated with a wide spectrum of disorders, including the recently discovered C3 glomerulopathy. Development of C3 glomerulopathy in the context of monoclonal gammopathy of renal significance after kidney transplantation is uncommon and very few cases have been published to date. We report on three cases of C3 glomerulopathy in the context of de novo monoclonal gammopathy after kidney transplantation., (Copyright © 2018 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
10. Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis.
- Author
-
Rodriguez Faba O, Palou J, Vila Reyes H, Guirado L, Palazzetti A, Gontero P, Vigués F, Garcia-Olaverri J, Fernández Gómez JM, Olsburg J, Terrone C, Figueiredo A, Burgos J, Lledó E, and Breda A
- Subjects
- Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local diagnosis, Postoperative Complications diagnosis, Prognosis, Prospective Studies, Retrospective Studies, Urinary Bladder Neoplasms diagnosis, Kidney Transplantation, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local therapy, Postoperative Complications mortality, Postoperative Complications therapy, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms therapy
- Abstract
Objectives: Bladder cancer (BC) in the transplanted population can represent a challenge owing to the immunosuppressed state of patients and the higher rate of comorbidities. The objective was to analyze the treatment of BC after renal transplant (RT), focusing on the mode of presentation, diagnosis, treatment options and predictive factors for recurrence., Material and Methods: We conducted an observational prospective study with a retrospective analysis of 88 patients with BC after RT at 10 European centers. Clinical and oncologic data were collected, and indications and results of adjuvant treatment reviewed. The Kaplan-Meier method and uni- and multivariate Cox regression analyses were performed., Results: A total of 10,000 RTs were performed. Diagnosis of BC occurred at a median of 73 months after RT. Median follow-up was 126 months. Seventy-one patients (81.6%) had non-muscle invasive bladder cancer, of whom 29 (40.8%) received adjuvant treatment; of these, six (20.6%) received bacillus Calmette-Guérin and 20 (68.9%) mitomycin C. At univariate analysis, patients who received bacillus Calmette-Guérin had a significantly lower recurrence rate (P=.043). At multivariate analysis, a switch from immunosuppression to mTOR inhibitors significantly reduced the risk of recurrence (HR 0.24, 95% CI: 0.053-0.997, P=.049) while presence of multiple tumors increased it (HR 6.31, 95% CI: 1.78-22.3, P=.004). Globally, 26 patients (29.88%) underwent cystectomy. No major complications were recorded. Overall mortality (OM) was 32.2% (28 patients); the cancer-specific mortality was 13.8%., Conclusions: Adjuvant bacillus Calmette-Guérin significantly reduces the risk of recurrence, as does switch to mTOR inhibitors. Multiple tumors increase the risk., (Copyright © 2017 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
11. C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II.
- Author
-
Martínez-Castelao A, Cases A, Coll E, Bonal J, Galceran JM, Fort J, Moreso F, Torregrosa V, Guirado L, and Ruiz P
- Subjects
- Adolescent, Adult, Aged, Anemia etiology, Anemia, Iron-Deficiency blood, Anemia, Iron-Deficiency drug therapy, Anemia, Iron-Deficiency etiology, Diabetic Nephropathies blood, Drug Administration Schedule, Erythropoietin administration & dosage, Female, Humans, Iron blood, Male, Middle Aged, Polyethylene Glycols administration & dosage, Renal Insufficiency, Chronic complications, Retrospective Studies, Young Adult, Anemia prevention & control, Erythropoietin therapeutic use, Hemoglobins analysis, Polyethylene Glycols therapeutic use, Renal Insufficiency, Chronic blood
- Abstract
Background and Objective: C.E.R.A. (continuous erythropoietin receptor activator, pegilated-rHuEPO ß) corrects and maintains stable hemoglobin levels in once-monthly administration in chronic kidney disease (CKD) patients. The aim of this study was to evaluate the management of anemia with C.E.R.A. in CKD patients not on dialysis in the clinical setting., Methods: Two hundred seventy two anemic CKD patients not on dialysis treated with C.E.R.A. were included in this retrospective, observational, multicentric study during 2010. Demographical characteristics, analytical parameters concerning anemia, treatment data and iron status were recorded., Results: C.E.R.A. achieved a good control of anemia in both naïve patients (mean Hemoglobin 11.6g/dL) and patients converted from a previous ESA (mean Hemoglobin 11.7g/dL). Most naïve patients received C.E.R.A. once monthly during the correction phase and required a low monthly dose (median dose 75 µg/month). The same median dose was required in patients converted from a previous ESA, and it was lower than recommended in the Summary of Product Characteristics (SPC). Iron status was adequate in 75% of anemic CKD patients, but only 50% of anemic patients with iron deficiency received iron supplementation., Conclusions: C.E.R.A. corrects and maintains stable hemoglobin levels in anemic CKD patients not on dialysis, requiring conversion doses lower than those recommended by the SPC, and achieving target hemoglobin levels with once-monthly dosing frequency both in naïve and converted patients.
- Published
- 2015
- Full Text
- View/download PDF
12. Angioplasty and stent treatment of transplant renal artery stenosis.
- Author
-
Del Pozo M, Martí J, Guirado L, Facundo C, Canal C, de la Torre P, Ballarín J, and Díaz JM
- Subjects
- Adult, Aged, Anticoagulants therapeutic use, Aspirin therapeutic use, Clopidogrel, Female, Follow-Up Studies, Humans, Hypertension, Renovascular etiology, Male, Middle Aged, Postoperative Complications diagnostic imaging, Prospective Studies, Renal Artery Obstruction complications, Renal Artery Obstruction diagnostic imaging, Risk Factors, Ticlopidine analogs & derivatives, Ticlopidine therapeutic use, Treatment Outcome, Ultrasonography, Angioplasty, Kidney Transplantation, Postoperative Complications therapy, Renal Artery Obstruction therapy, Stents
- Abstract
Transplant renal artery stenosis is a major complication that requires a therapeutic approach involving surgery or angioplasty. The aim of this study was to analyse the evolution of renal transplant patients with renal allograft artery stenosis treated by angioplasty and stent placement. Thirteen patients were diagnosed with transplant renal artery stenosis. Clinical suspicion was based on deterioration of renal function and/or poorly controlled hypertension with compatible Doppler ultrasound findings. The diagnosis was confirmed by arteriography, performing an angioplasty with stent placement during the same operation. A progressive improvement in renal function was observed during the first 3 months after the angioplasty, and renal function then remained stable over 2 years. In addition, blood pressure improved during the first 2 years, and as a consequence there was no need to increase the average number of anti-hypertensive drugs administered (2.5 drugs per patient). In conclusion, angioplasty with stent placement is a safe and effective procedure for the treatment of transplant renal artery stenosis.
- Published
- 2012
- Full Text
- View/download PDF
13. [Renal retransplantation: risk factors and results].
- Author
-
Arce J, Rosales A, Caffaratti J, Montlleó M, Guirado L, Díaz JM, and Villavicencio H
- Subjects
- Adult, Female, Humans, Male, Postoperative Complications epidemiology, Postoperative Complications surgery, Reoperation, Retrospective Studies, Risk Factors, Treatment Outcome, Kidney Transplantation adverse effects
- Abstract
Objective: to review our experience in renal retransplantations., Materials and Methods: we carried out a retrospective study on 71 patients with retransplantation performed between 1980 and 2005. We studied: the characteristics of the recipient and graft, surgery data, causes of loss of the graft, number of rejects and transplantectomies and, survival of the graft., Results: the most frequent cause of graft loss was chronic rejection. The causes of first graft loss were not associated with a greater loss of the second graft (p>0.05). The percentage of anti-HLA antibodies increased in the second transplant in comparison to the first (17.23±27.91% vs. 1.21±7.43%) (p=0.001), however, it was not correlated with a significant increase in loss of the second graft (p=0.320). There were no significant differences between the complications of the first and second transplants (p>0.05) and they were not associated with graft loss (p>0.05). The patients with a transplantectomy in the first transplant presented a risk 8.5 times higher of undergoing a second one (p=0.0001; OR: 8.54; CI: 95% 0.941 - 77.501). The most frequent cause of transplantectomies in the second transplant was acute rejection. Acute rejection as a cause for transplantectomy in the first transplant proved to be an independent risk factor of transplantectomy of the second transplant (p=0.009). The mean survival of the second graft was 5.08±4.81 years, higher than the first transplant (p=0.133). The survival of the graft at 1.5 and 10 years was 83%, 75% and 52%, respectively., Conclusions: the survival of the second transplant was not lower than the first, neither was there an increase in the number of complications., (Copyright © 2010 AEU. Published by Elsevier Espana. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
14. [Incompatible living donors in kidney tranplantation].
- Author
-
Guirado L
- Subjects
- Agglutinins blood, Histocompatibility Testing, Humans, Immunosuppression Therapy, Tissue and Organ Procurement, Histocompatibility immunology, Kidney Transplantation, Living Donors
- Abstract
Renal transplant is the best option of treatment of chronic kidney disease and the shortage of cadaveric donors has caused the rapid increase of living donor programs. Provided that an important proportion of the donor-recipient pairs are incompatible between them, ABO incompatibility or positive cross-match test, one of the most important challenges of last decade, has been the solution of the above mentioned problem. For it there have begun the crossed-over transplant programs (also called donors' exchange programs) in his different combinations and these kind of transplants has been consolidated by an excellent results. To eliminate the titles of anti-HLA antibodies and the isoaglutinines we have different resources, beeing the most importants plasmapheresis, the immunoadsortion, immunoglobulin infusion, Rituximab use and splenectomy. They need all of them of the concomitant use of a powerful immunosuppression and of a suitable antiinfectious prevention. The results obtained with the incompatible donors are nowadays excellent and totally comparable to the obtained ones using living compatible donors.
- Published
- 2010
- Full Text
- View/download PDF
15. [Chronic nephropathy in non-kidney transplantation: [prevention, early diagnosis and management].
- Author
-
Guirado L, Almenar L, Alonso A, Castroagudín JF, Hernández D, Morales JM, Usetti P, and Varo E
- Subjects
- Biopsy, Early Diagnosis, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents classification, Incidence, Kidney Function Tests, Male, Prevalence, Renal Replacement Therapy, Risk Factors, Vasoconstriction, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic economics, Kidney Failure, Chronic epidemiology, Kidney Failure, Chronic etiology, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic prevention & control, Kidney Failure, Chronic therapy, Postoperative Complications diagnosis, Postoperative Complications economics, Postoperative Complications epidemiology, Postoperative Complications etiology, Postoperative Complications physiopathology, Postoperative Complications prevention & control, Postoperative Complications therapy, Transplantation
- Abstract
Transplant from solid nonrenal organ has experienced an important increase in the last decades. It is due to the increasing improvement of the results obtained with the above mentioned transplants. Parallel, many nonrenal transplanted patients have developed a chronic renal failure that has determined, in some cases, the need of beginning the substitution of renal function by means of dialysis and/or transplant. The origin of the same one is multifactorial and the consequences derived from it are very important so much in morbimortality as of economic nature for the set of the system. The present review tries to help to the identification of risk factors of renal insufficiency in the nonrenal transplanted patient and to determine which might be the basic concepts of prevention, early diagnosis and of derivation to the nephrologist expert in transplants and renal dysfunction. Finally, we check the possibilities of managing of the immunosuppressive treatment and substitution of renal function by means of dialysis and/or simple or double transplant.
- Published
- 2009
- Full Text
- View/download PDF
16. [Pregnancy in recipients of kidney transplantation: effects on mother and child].
- Author
-
Díaz JM, Canal C, Giménez I, Guirado L, Facundo C, Solà R, and Ballarín J
- Subjects
- Adolescent, Adult, Female, Humans, Infant, Newborn, Pregnancy, Prospective Studies, Kidney Transplantation, Pregnancy Outcome
- Abstract
When the field of transplantation was first developing, physicians worried about the teratogenicity of immunosuppressive medications and considered pregnancy ill-advised. The purpose of this study is to analyze pregnancy after kidney transplantation and their consequences on mother, graft and child. We review ten pregnant women with kidney transplantation, average of 29 years old and 44 months post-kidney transplantation. The mean glomerular filtration rate was 64 ml/min and the immunosuppression was with prednisone and tacrolimus. We analyze outcomes of different variables before and during pregnancy, and after labour. Pregnancy finished in nine of ten patients. Three patients needed cesarean section and only one patient had a miscarriage on the first term. Blood arterial pressure increased at the end of pregnancy and the creatinine level was stable with a few increase of proteinuria at the third term. We increased the tacrolimus dose to obtain the correct blood levels and any rejection was detected. We had only one patient with preeclampsia that we solved with a cesarean section. Labours were a mean of 37.2 weeks and the mean birth weight of infant was 2,809 grams. Two newborns had prematurity without structural malformations. Pregnancy after kidney transplantation is safe with prednisone and tacrolimus when the renal function is good, proteinuria doesn't exist and blood pressure is controlled.
- Published
- 2008
17. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
- Author
-
Guirado L, Rabella N, Díaz JM, Facundo C, Maderuelo A, Margall N, Silva I, García-Maset R, Calabia J, Giménez I, Garra N, Solà R, and Ballarín JA
- Subjects
- Administration, Oral, Adolescent, Adult, Ganciclovir administration & dosage, Humans, Incidence, Risk Factors, Valganciclovir, Antiviral Agents administration & dosage, Cytomegalovirus Infections epidemiology, Cytomegalovirus Infections prevention & control, Ganciclovir analogs & derivatives, Kidney Transplantation
- Abstract
Unlabelled: Prophylactic and pre-emptive therapy with oral valganciclovir for cytomegalovirus infection in renal transplant recipients., Background: Cytomegalovirus infection is a very important health problem in solid organ transplant recipients (SOT). Once-daily valganciclovir has been shown to be as clinically effective and well tolerated as oral ganciclovir tid in the prevention of CMV infection in high risk SOT recipients., Methods: The aim of the present study was to evaluate the incidence and severity of CMV disease in 150 renal transplant recipients that received either prophylactic [high risk group (HR), N = 66] or pre-emptive [low risk group (LR), N = 84] therapy with oral valganciclovir (900 mg/day vo) for three months according to their basal risk. Patients were monitored for signs and symptoms of CMV disease and CMV plasma viral load was assessed weekly., Results: A total of 31 patients (47%) of the HR and 26 patients (31%) of the LR presented a positive CMV PCR result. Twelve patients (14.3%) in the LR that had a high viral load (CMV PCR > 1,000 copies/mL) but remained asymptomatic received pre-emptive therapy. Four patients (4.7%) in the LR, after an average time of 35 days after transplant and two patients (4.5%) in the HR, after prophylactic treatment was completed, developed CMV disease. The disease was mild-moderate in most of the cases. Those patients that developed CMV disease responded to treatment with iv ganciclovir for 14 days followed by treatment with oral valganciclovir for up to three months., Conclusion: Prophylactic treatment with oral valganciclovir for CMV prevention is only required in high risk solid organ transplant recipients.
- Published
- 2008
18. [Why renal transplant from living donors gives better results than cadaver renal transplant?].
- Author
-
Guirado L, Vela E, Clèries M, Díaz JM, Facundo C, and García-Maset R
- Subjects
- Adolescent, Adult, Aged, Cadaver, Female, Humans, Male, Middle Aged, Treatment Outcome, Kidney Transplantation mortality, Living Donors
- Abstract
Background: According to literature, patient and graft survival is better in living donor renal transplants (LRT) than in cadaver renal transplants (CRT)., Objective: To study factors that determine the best results in LRT related to those of CRT, found in univariate studies., Patients and Methods: Renal transplants (RT) done in Catalonia during the 1990-2004 period, performed in patients over 17 years (135 LRT and 3.831 CRT), have been analyzed (retransplants were not included). The data come from the Renal Patients Transplant Registry (RMRC). Student's t-test and chi2 test have been used for mean and for proportions comparisons, respectively. To analyze univariate and multivariate survival, actuarial method and Cox regression have been used, respectively. Estimated creatinine clearance has been studied and its data have been showed through Selwood modified Analysis., Results: As it happens with other great RT patients series, the RMRC analysis, globally and without any adjustment, shows that patient and graft survival in LRT is better than that obtained with CRT. When we studied which variables explain these results, we found that main factors were smaller recipient age and the short time on dialysis. The great influence of both factors has been published in a large number of papers, explaining the differences obtained on the transplanted renal patient survival., Conclusions: Once adjusted the analysis by the different factors that influence the survival of the patient and the graft, there are no differences in the obtained results, since the best outcomes of the TRV are due to factors like the smaller recipient age and the advanced TR.
- Published
- 2008
19. [The living kidney donor: laparoscopy versus open surgery].
- Author
-
Facundo C, Guirado L, Díaz JM, Sainz Z, Alcaraz A, Rosales A, and Solà R
- Subjects
- Age Factors, Follow-Up Studies, Graft Rejection, Humans, Middle Aged, Randomized Controlled Trials as Topic, Risk Factors, Time Factors, Tissue and Organ Harvesting, Waiting Lists, Kidney Transplantation, Laparoscopy, Living Donors, Nephrectomy
- Abstract
Introduction: Living renal donors are an important source of transplanted kidneys due to the number of patients on waiting list is progressively increasing. On the other side, they allow the pre-emptive kidney transplantation. With the aim of reducing donor obstacles such as pain, hospital stay or cosmetic results and in creasing the number of living donors, in 1995 Ratner performed the first laparoscopic nephrectomy (LLDN). By now, LLDN is a routine procedure in more than 200 centres worldwide., Methods: Literature databases are searched. We have reviewed the data from our experience after performing 50 laparoscopic nephrectomies., Results: Preoperative living donor assessment and contraindications to LLDN do not differ from the open approach. Results are very influenced by the surgeon's situation in the learnig curve. Operating times use to be longer in laparoscopic procedures. The overall complication rate and mortality of LLDN are the same for both of the approaches. Conversion to open-donor nephrectomy has been reported in 0-13% of cases (8% in our data). Postoperative pain and donor estimated blood loss are lower for LLDN, as well as the convalescence period. To avoid the possible negative effects of the laparoscopic technique on kidney graft function a lot of method's variations have been proposed for gaining access and harvesting the kidney, including the hand-assistance techniques, with the aim of minimizing operative time, pneumoperitoneus negative effect on graft function and warm ischemia time (WIT). The higher WIT is not related to delayed graft function or acute rejections when it is less than ten minutes. Delayed graft function does not differ in both approaches and creatinine values from the first month until the third year after transplantation show no differences in randomized studies., Conclusions: The laparoscopic approach to harvest the allograft from the living donor is a save and effective technique and has the advantage of being less invasive and allowing the donor a shorter convalescence. It has no negative effects on allograft function in the short term follow-up. Further studies are required to evaluate long term donor complications and allograft function and survival.
- Published
- 2005
20. [Outcomes of transplantation from living renal donor].
- Author
-
Guirado L, Díaz JM, Facundo C, Alcaraz A, Rosales A, and Solà R
- Subjects
- Anti-Inflammatory Agents administration & dosage, Cadaver, Follow-Up Studies, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents administration & dosage, Laparoscopy, Length of Stay, Middle Aged, Mycophenolic Acid administration & dosage, Mycophenolic Acid analogs & derivatives, Nephrectomy, Prednisone administration & dosage, Survival Analysis, Tacrolimus administration & dosage, Time Factors, Treatment Outcome, Kidney Transplantation, Living Donors
- Abstract
Living donors represent 30% of our kidneys for renal transplantation. Laparoscopic nephrectomy is the best surgical procedure to obtain them due to its clear advantages such as low morbidity, less blood supply and donor time in hospital. From March 2002 to August 2004 we performed 50 laparoscopic nephrectomies for renal transplantation. Kidneys were transplanted to recipients receiving tacrolimus 0.1 mg/kg/bid, mycophenolate mofetil 1 g/bid and prednisone 0.5-1 mg/kg/day p.o 48 hours before transplantation. Mean time for surgery was 170 minutes (120-260), warm ischaemia time 3.1 minutes (1.5-10) and cold ischaemia time 1.27 hours (0.85-4). Mean bleeding was 270 cc (100-900) and donor time in hospital 5.5 days (3-9). Four cases required conversion of the laparoscopic procedure to open surgery because of bleeding. 72 hours post-transplant mean plasmatic creatinine was 170 micromol/l. None of the patients suffered delayed graft function. 18% presented acute rejection. Survival of donor and recipient was 100% at 1 year and graft survival was 94% at 1 year (kidney losses were due to acute rejection, severe acute pancreatitis and surgical problem).
- Published
- 2005
21. [Assessment of the living renal donor. Analysis of extra-renal pathology as a limitation for donation].
- Author
-
Díaz JM, Guirado L, Facundo C, García-Maset R, and Solà R
- Subjects
- Age Factors, Aged, Blood Glucose analysis, Body Mass Index, Cadaver, Diabetes Mellitus, Type 2 complications, Female, Humans, Hypertension complications, Hypertension drug therapy, Infections complications, Male, Middle Aged, Neoplasms complications, Nephrectomy, Postoperative Complications, Virus Diseases complications, Weight Loss, Kidney Transplantation, Living Donors
- Abstract
The goal of the donor evaluation is to ensure the suitability, safety and well being of the donor. In order to avoid important omissions, the evaluation of potential living kidney donors should be carried according to a protocol that includes a logical sequence of complementary explorations. Old age alone is not an absolute contraindication to donation but the evaluation should be more rigorous, because increased age may be associated with more post-operative complications after nephrectomy and renal function and long term graft survival could be shorter than the ones obtained from younger living donors. A body mass index of more than 35 kg/m2 should be an absolute contraindication to renal donation. Between 30 and 35 kg/m2 the donor evaluation should be more rigorous and it should be recommended to lose weight before nephrectomy. Hypertension is one of the most common reasons to declare a potential kidney donor unsuitable. Evidence of organ damage is an absolute contraindication to kidney donation. The donation is only reasonable when hypertension is well controlled with less than two drugs. To excluded diabetes mellitus all donors should have a fasting plasma glucose measurement. Diabetes mellitus is an absolute contraindication to living donation such as an impaired glucose tolerance or impaired fasting glucose with a family history of type 2 diabetes mellitus. Another contraindication to living donation is malignant disease, and the same standards should be adopted for cadaveric donors. The exceptions are low-grade non-melanoma skin cancer and carcinoma in situ of the uterine cervix. The presence of active infection usually precludes donation. It is very important to perform a routine test for viral infections. HIV, hepatitis B and C infection of the donor are usually a contraindication to living donor. CMV donor and recipient status should be taken into account before transplantation, and the recipients at risk for CMV disease should recieve prophylactic treatment according to the transplant unit policy.
- Published
- 2005
22. [Living donor nephrectomy for kidney transplantation. Experience in the first two years].
- Author
-
Alcaraz A, Rosales A, Palou J, Caffaratti J, Montlleó M, Segarra J, Ponce de León J, Huguet J, Errando C, Díaz JM, Guirado L, and Villavicencio H
- Subjects
- Humans, Living Donors, Time Factors, Kidney Transplantation physiology, Laparoscopy, Nephrectomy methods
- Abstract
Objectives: Laparoscopic surgery offers potential advantages in terms of diminishment of postoperative pain, shorter hospital stay, faster convalescence, and better cosmetic results. These advantages may increase kidney donation, making donation be accepted by more candidates. We report our first 2 years' experience with laparoscopic donor nephrectomy, Methods: Between March 2002 and February 2004 we performed 38 laparoscopic living donor nephrectomies for kidney transplantation. The technique of choice was the transperitoneal laparoscopic approach with four trocars, usually three of them from the start of the procedure--two 10-12 mm and one 5 mm--, and a 6.5 cm perumbilical midline incision for kidney retrieval at the end of the procedure., Results: Receptor and donor survivals were 100%. Graft survival was 97.6%. There was not any case of delayed graft function. Donor: Mean operative time was 161 minutes (115-260). Mean estimated blood loss was 270 ml (100-1200). Three patients required blood transfusions, 2 units of packed red blood cells each. Mean hospital stay was 5.1 days (3-11). Mean warm ischemia time was 3.2 min. (2-10). Conversion to open surgery was necessary in four cases. Receptor: there have been three significant complications requiring surgical repair: one case of low arterial flow, one vesico ureteral leak, and one midurethra stenosis. Initial renal function: mean serum creatinine at one month was 147mmol/l, with a trend to improve to 126 mmol/l at one year, which is considered optimum. First postoperative day mean serum creatinine was 192mmol/l and the nadir was on second postoperative day with a value of 152mmol/l., Conclusions: We believe laparoscopic living donor nephrectomy is a real alternative to open surgery because it offers better recovery to the donor with the same capacity to preserve renal function in the receptor.
- Published
- 2004
23. [Use of intestine and preparation of the lower urinary tract for kidney transplantation].
- Author
-
Palou J, Caparrós J, Guirado L, and Solá R
- Subjects
- Humans, Intestines surgery, Preoperative Care, Urinary Bladder surgery, Urinary Diversion, Kidney Transplantation
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.